Webinar: New Targeted Therapy for Advanced GE Junction Adenocarcinoma – Zolbetuximab (Vyloy)

Dr. Samuel J. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and esophageal program. In this webinar, he helps us understand who is eligible for this new therapy, the risks and benefits of zolbetuximab, and what research shows about its effectiveness.

His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies, and the intersection of genomics and immune-mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers.

Please take two minutes to complete this short survey to give us your feedback about the webinar.

Generous Sponsors that make possible ECAN’s Webinar Series